These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2971634)

  • 1. Tetranactin, a macrotetrolide antibiotic, suppresses in vitro proliferation of human lymphocytes and generation of cytotoxicity.
    Callewaert DM; Radcliff G; Tanouchi Y; Shichi H
    Immunopharmacology; 1988; 16(1):25-32. PubMed ID: 2971634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive and anti-proliferative effects of a macrotetrolide antibiotic, tetranactin.
    Tanouchi Y; Shichi H
    Immunology; 1988 Mar; 63(3):471-5. PubMed ID: 3258281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive effects of polynactins (tetranactin, trinactin and dinactin) on experimental autoimmune uveoretinitis in rats.
    Tanouchi Y; Shichi H
    Jpn J Ophthalmol; 1987; 31(2):218-29. PubMed ID: 3499534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrocortisone suppresses the generation of nonspecific "anomalous" killers but not specific cytolytic T lymphocytes in human mixed lymphocyte-tumor cultures.
    Muul LM; Gately MK
    J Immunol; 1984 Mar; 132(3):1202-7. PubMed ID: 6198383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.
    Thiele DL; Lipsky PE
    J Immunol; 1986 Feb; 136(3):1038-48. PubMed ID: 2934477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the inhibitory effects of immunosuppressive agents cyclosporine, tetranactin, and didemnin B on human T cell responses in vitro.
    Teunissen MB; Pistoor FH; Rongen HA; Kapsenberg ML; Bos JD
    Transplantation; 1992 Apr; 53(4):875-81. PubMed ID: 1566353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human interleukin 4 regulates the phenotype of lymphocytes generated during mixed lymphocyte culture and inhibits the IL-2-induced development of LAK function in normal and leukaemic cells.
    Jin BQ; Lopez AF; Gillis S; Juttner CA; Vadas MA; Burns GF
    Leuk Res; 1989; 13(4):297-305. PubMed ID: 2523990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine blocks the activation of antigen-dependent cytotoxic T lymphocytes directly by an IL-2-independent mechanism.
    Havele C; Paetkau V
    J Immunol; 1988 May; 140(10):3303-8. PubMed ID: 2966195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fucose-activated killer (FAK) cells: anomalous killers with augmented cytotoxic activity.
    Stanková J; Rola-Pleszczynski M
    J Immunol; 1985 Dec; 135(6):3719-28. PubMed ID: 2415584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OK-432 and IL-2-augmented cytotoxicity of human natural killer cells and cytotoxic T lymphocytes at the clonal level.
    Gravekamp C; Vreugdenhil R; Bolhuis RL
    FEMS Microbiol Immunol; 1988 Jan; 1(1):31-9. PubMed ID: 2978812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.
    Roth AD; Dupuis S; Alberto P
    Clin Exp Immunol; 1995 Aug; 101(2):362-8. PubMed ID: 7648722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated allogeneic NK cells as suppressors of alloreactive responses.
    Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells.
    Mingari MC; Ponte M; Bertone S; Schiavetti F; Vitale C; Bellomo R; Moretta A; Moretta L
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1172-7. PubMed ID: 9448304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leu-Leu-OMe sensitivity of human activated killer cells: delineation of a distinct class of cytotoxic T lymphocytes capable of lysing tumor targets.
    Thiele DL; Lipsky PE
    J Immunol; 1986 Aug; 137(4):1399-406. PubMed ID: 3488348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures.
    Bejarano MT; de Waal Malefyt R; Abrams JS; Bigler M; Bacchetta R; de Vries JE; Roncarolo MG
    Int Immunol; 1992 Dec; 4(12):1389-97. PubMed ID: 1286062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment of human peripheral blood lymphocytes with interleukin-2 or dexamethasone does not alter their response to Met-Enkephalin in a NK-cytotoxic assay.
    Martin-Kleiner I; Gabrilovac J
    Immunopharmacol Immunotoxicol; 1996 Feb; 18(1):37-57. PubMed ID: 8683038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells.
    Buurman WA; Ruers TJ; Daemen IA; van der Linden CJ; Groenewegen G
    J Immunol; 1986 Jun; 136(11):4035-9. PubMed ID: 2939138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytotoxicity of the lymphocytes of melanoma patients against autologous tumor cells and its in vitro enhancement].
    Bykovskaia SN; Iobadze MS; Kupriianova TA; Demidov LV
    Biull Eksp Biol Med; 1987 Jan; 103(1):86-9. PubMed ID: 2948576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.